Time to drug-resistant tuberculosis treatment in a prospective South African cohort

Published Date:

11/30/2018

Source:

Global Pediatric Health

Authors:

van de Water, B., Bettger, J. P., Silva, S., Humphreys, J., Cunningham, C. K., & Farley, J. E. 

External link

Original Article

This study examined time to treatment initiation by age among a prospective cohort with drug-resistant tuberculosis (DR-TB). Participants aged 13 years or older nested within a cluster-randomized trial in 2 South African provinces were evaluated. Outcomes were treatment initiation within 5 days of DR-TB diagnosis (National Tuberculosis Program guidelines) and days from diagnosis to treatment. A total of 521 participants met inclusion criteria. Eighty-two patients (16%) met national guidelines; median time to treatment was 11 days (range = 0-180). No patient (age, sex, prior TB history, HIV status) or health system characteristics (geographic urban/rural location, province) were associated with treatment initiation per guidelines except geographic location (t = 3.64, degrees of freedom = 1, P = .0003). One in 6 individuals with DR-TB received treatment per guidelines, and average time to treatment was 11 days. Strategies are needed to decrease treatment delays and meet the recommended guidelines for treatment for patients of all ages.

Events

«

October 2020

»
S
M
T
W
T
F
S
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Projects

FlexDx-TB: A flexible, user-friendly model of...

We have developed a web-based model that allows decision-makers to input local epidemiological and economic values and receive...

Read More

Modeling the impact of spatially targeted TB...

We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

Understanding and Improving the Effectiveness...

The goal of this project is to construct a mathematical model of the laboratory network for diagnosis of infectious diseases in...

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More